20 trends tracked about this subject — the full history, oldest to newest below.
Employer health plans are increasingly dropping GLP-1 weight-loss drug coverage as cash prices soar and 2027 options remain uncertain.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A novel injectable drug called CBL-514 is drawing attention for reducing visceral fat and targeting fat cells without Ozempic or surgery.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Roche has halted the development of emugrobart, a muscle-preserving obesity drug candidate, following a failed interim analysis.
Health coverage examines nutritional support and strength training for individuals taking GLP-1 medications.
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly’s 48% revenue surge eclipses a weak earnings report from The Trade Desk, reshaping market expectations for biotech and ad tech alike.
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
New analysis suggests that weight loss achieved through obesity drugs does not necessarily translate into improved mental health or better job prospects.
Insurance executives and employers are redefining access to GLP-1 weight-loss medications amid shifting coverage trends and affordability challenges.
Patients are struggling to afford weight loss prescriptions as Massachusetts reduces coverage for these high-cost medications.
Medicare has introduced a temporary pilot program designed to expand patient access to GLP-1 weight-loss medications.